2. Search Result
Search Result
Results for "

Mark2

" in MedChemExpress (MCE) Product Catalog:

8

Inhibitors & Agonists

2

Antibodies

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-139604
    PCC0208017
    3 Publications Verification

    		 MARK Apoptosis Cancer
    PCC0208017 is a microtubule affinity regulating kinases (MARK3/MARK4) inhibitor with IC50s of 1.8 and 2.01 nM, respectively. PCC0208017 has much lower inhibitory activity against MARK1 and MARK2, with IC50s of 31.4 and 33.7 nM, respectively. PCC0208017 suppresses glioma progression in vitro and in vivo. PCC0208017 disrupts microtubule dynamics and induces G2/M phase cell cycle arrest and cell apoptosis. PCC0208017 demonstrates robust antitumor activity in vivo and displays good BBB permeability .
    PCC0208017
  • HY-120877
    MRT199665

    		MARK Salt-inducible Kinase (SIK) AMPK Apoptosis Cancer
    MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively . MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells [2]. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 .
    MRT199665
  • HY-148062
    RSS0680

    		PROTACs CDK AAK1 Cyclin G-associated Kinase (GAK) Salt-inducible Kinase (SIK) LIM Kinase (LIMK) Wee1 SnRK Others
    RSS0680 is a small noncoding RNA (sRNA) targeting the mRNA ribosome binding site (RBS) and a PROTAC with protein kinase degradation activity (Pink: FLT3-IN-17 (HY-148070); Black: Linker (HY-W041970); Blue: E3 ligase Ligand (HY-112078)). RSS0680 competitively binds to RBS through the conserved CCUCCUCCC anti-Shine-Dalgarno (aSD) sequence and inhibits the translation initiation of target genes. RSS0680 can interact with the DUF1127 protein CcaF1, regulate its own stability and participate in bacterial oxidative stress defense, enhancing the host's resistance to heat shock and oxidative damage by affecting pathways such as C1 metabolism and pyruvate dehydrogenase complex. RSS0680 degrades AAK1, CDK1, CDK16, CDK2, CDK4, CDK6, EIF2AK4, GAK, LATSl, LIMK2, MAPK6, MAPKAPK5, MARK2, MARK4, MKNK2, NEK9, RPS6KB1, SIK2, SNRK, STK17A, STK17B, STK35, and WEEl. RSS0680 can be used to study diseases or disorders mediated by aberrant kinase activity and regulatory mechanisms of noncoding RNAs in α-proteobacteria[1][2].
    RSS0680
  • HY-RS24069
    Mark2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mark2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Mark2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mark2 Rat Pre-designed siRNA Set A
    Mark2 Rat Pre-designed siRNA Set A
  • HY-RS08150
    MARK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    MARK2 Human Pre-designed siRNA Set A contains three designed siRNAs for MARK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    MARK2 Human Pre-designed siRNA Set A
    MARK2 Human Pre-designed siRNA Set A
  • HY-RS17609
    Mark2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Mark2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Mark2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Mark2 Mouse Pre-designed siRNA Set A
    Mark2 Mouse Pre-designed siRNA Set A
  • HY-120877A
    (R)-MRT199665

    		MARK Salt-inducible Kinase (SIK) AMPK Apoptosis Cancer
    (R)-MRT199665 is an isomer of MRT199665 (HY-120877). MRT199665 is a potent and ATP-competitive, selective MARK/SIK/AMPK inhibitor with IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively. MRT199665 causes apoptosis in MEF2C-activated human acute myeloid leukemias (AML) cells. MRT199665 inhibits the phosphorylation of SIK substrate CRTC3 at S370 [2] .
    (R)-MRT199665
  • HY-182743
    OICR19451

    		AMPK MARK YAP Cancer
    OICR19451 is an orally active dual NUAK1/NUAK2 and MARK2/MARK3 kinase inhibitor, with IC50 values of 12 nM and 10 nM against NUAK1 and NUAK2, and 101 nM and 124 nM against MARK2 and MARK3, respectively. OICR19451 modulates the Hippo signaling pathway, increases the phosphorylation level of YAP, enhances the cytoplasmic localization of YAP/TAZ, and inhibits the expression of oncogenes. OICR19451 inhibits cancer cell growth, reduces metastasis, promotes tumor capsule formation, and improves mouse survival in an orthotopic breast cancer model. OICR19451 can be used for research related to triple-negative breast cancer .
    OICR19451

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: